NCT07200830View on ClinicalTrials.gov

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,524

Participants

Timeline

Start Date

October 8, 2025

Primary Completion Date

September 9, 2034

Study Completion Date

September 9, 2034

Conditions
Metastatic Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Interventions
DRUG

Lutetium Lu 177 Vipivotide Tetraxetan

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Patient Monitoring

Undergo PSA monitoring

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Bone Scan

Undergo Bone Scan

PROCEDURE

PSMA PET Scan

Undergo PSMA PET Scan

PROCEDURE

MRI

Undergo MRI

OTHER

Questionnaire Administration

Ancillary studies

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER